|
TMEM64 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.74438241629105E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.27700089286509E-11 |
| Normal-vs-Stage2 |
3.54300000000585E-05 |
| Normal-vs-Stage3 |
1.27849952846759E-11 |
| Normal-vs-Stage4 |
1.63213886850144E-12 |
| Stage1-vs-Stage2 |
3.677600E-01 |
| Stage1-vs-Stage3 |
1.666980E-01 |
| Stage1-vs-Stage4 |
5.601100E-04 |
| Stage2-vs-Stage3 |
8.954300E-02 |
| Stage2-vs-Stage4 |
2.862200E-03 |
| Stage3-vs-Stage4 |
6.149900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.40203429263875E-13 |
| Normal-vs-AfricanAmerican |
1.06470054994645E-10 |
| Normal-vs-Asian |
1.97999999729248E-08 |
| Caucasian-vs-AfricanAmerican |
1.307560E-01 |
| Caucasian-vs-Asian |
8.895200E-01 |
| AfricanAmerican-vs-Asian |
2.001600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.38964445190504E-13 |
| Normal-vs-Female |
4.97668573018473E-12 |
| Male-vs-Female |
2.751600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.47800002739496E-10 |
| Normal-vs-Age(41-60Yrs) |
9.43499722794172E-11 |
| Normal-vs-Age(61-80Yrs) |
1.63102864547682E-12 |
| Normal-vs-Age(81-100Yrs) |
2.458700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.757200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.167640E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.894200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.433000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.056200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.282000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.43489999998781E-07 |
| Classical-VS-Follicular |
1.750000E-02 |
| Classical-VS-Other |
8.703400E-01 |
| Classical-VS-Normal |
1.68931535426964E-12 |
| Tall-VS-Follicular |
2.4074999993573E-08 |
| Tall-VS-Other |
2.690000E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
5.966000E-01 |
| Follicular-VS-Normal |
1.162720E-04 |
| Other-VS-Normal |
9.809800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.57480003984512E-09 |
| Normal-vs-N1 |
5.06927833043846E-13 |
| N0-vs-N1 |
3.938100E-03 |
|
|
